Achieved proof-of-mechanism for Wave’s RNA editing platform; restoring levels of wild-type (edited) M-AAT that are consistent with the heterozygous “MZ” genotype with low risk of AATD lung and liver ...
Wave Life Sciences Ltd. (NASDAQ:WVE) stock is trading higher on Wednesday after the company revealed proof-of-mechanism data from the ongoing Phase 1b/2a RestorAATion-2 study of WVE-006 in alpha-1 ...
Wave Life Sciences said today its alpha-1 antitrypsin deficiency (AATD) candidate WVE-006 succeeded in the first-ever clinical demonstration of RNA editing in humans by achieving positive ...
Ever felt like your dog just gets you? You're not imagining it. 2024 research published in Advanced Science revealed that the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results